The impact of surgical resection in early onset colorectal cancer patients with liver limited disease.

A Andrea Pretta (Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy) F Francesca Bergamo F Federica Marmorino F Federica Bertuzzi (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) P Pina Ziranu (Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy) K Krisida Cerma (Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy) P Paolo Ciracì F Federica Manoni (Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy) C Clelia Donisi (Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy) M Maria Caterina De Grandis (Medical Oncology 1, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy) A Ada Taravella S Silvia Marchesi (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy) V Valeria Pusceddu (Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy) G Giulia Maddalena (Medical Oncology 1, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy) R Roberta Fazio (Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, NA, Italy) R Riccardo Giampieri F Filippo Pietrantonio C Chiara Cremolini S Sara Lonardi M Mario Scartozzi (Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy)

Abstract

e15569 Background: Recent studies have shown an increased incidence of early-onset CRC (EO-CRC), particularly in advanced stages and with metastatic disease. Our study aimed to evaluate the role of metastasectomies related to the clinical and molecular characteristics of EO-CRC patients with liver metastases compared to late-onset CRC (LO-CRC) patients. Methods: We retrospectively collected data from 1123 stage IV colorectal cancers, including 782 with liver metastases, from 5 different Italian institutions. The main objective of the study was to compare the overall survival of liver metastatic EO-CRC and LO-CRC patients who underwent metastasectomy versus those who were not resected. Results: Liver resected EO-CRCs patients showed a statistically significant lower mOS than liver resected LO-CRCs (44.0 vs 64.0 months, p < 0.0001 ). mPFS was also statistically significant lower in EO-CRCs (13.0 vs 17.0, p < 0.0001 ). Same outcomes were found in RAS mut subgroup (37.0 vs 52.0 months, p < 0.0001) and in RAS/BRAF wild-type subgroup (50.0 vs 81.0 months, p < 0.0001). EO-CRC patients showed a higher prevalence of TP53 alterations (56.2%) and a lower of APC mutation (29.9%). EO-CRCs presented a higher frequency of ARID1A (4.4%) and CTNNB1 (3.0%) alterations. Conclusions: The results indicate a worse overall prognosis for EO-CRC patients undergoing metastasectomy compared to late-onset patients. This outcome appears to occur independently of the molecular status. These observations could have a considerable impact on clinical practice and research.

Article Details

Volume / Issue Vol. 43, Issue 16_suppl
Published June 01, 2025
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (20)

A

Andrea Pretta

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

F

Francesca Bergamo

F

Federica Marmorino

F

Federica Bertuzzi

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

P

Pina Ziranu

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

K

Krisida Cerma

Medical Oncology 1, Veneto Institute of Oncology IOV-IRCCS, Padua, Italy

P

Paolo Ciracì

F

Federica Manoni

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

C

Clelia Donisi

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

M

Maria Caterina De Grandis

Medical Oncology 1, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy

A

Ada Taravella

S

Silvia Marchesi

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy

V

Valeria Pusceddu

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy

G

Giulia Maddalena

Medical Oncology 1, Veneto Institute of Oncology IOV-IRCSS, Padua, Italy

R

Roberta Fazio

Medical Oncology Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, NA, Italy

R

Riccardo Giampieri

F

Filippo Pietrantonio

C

Chiara Cremolini

S

Sara Lonardi

M

Mario Scartozzi

Medical Oncology Unit, University Hospital and University of Cagliari, Cagliari, Italy